CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $60.82M, above the global median of $16.24M
- FinancialsAltman Z-Score 6.87: safe zone
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
640.47MUSDvs all stocks (USD)
Trailing P/E
21.50xvs Biotechnology peers
Revenue (TTM)
389.42MUSDvs all stocks (USD)
Profit Margin
7.88%vs Biotechnology peers
Beta
1.45xvs all stocks
52-Week Change
-35.34%vs all stocks
Market Capitalization
640.47MUSDvs all stocks (USD)
Enterprise Value
498.29MUSDvs all stocks (USD)
Trailing P/E
21.50xvs Biotechnology peers
Forward P/E
30.00xvs Biotechnology peers
PEG Ratio
-0.0896xvs Biotechnology peers
Price to Sales (TTM)
1.64xvs Biotechnology peers
Price to Book (MRQ)
2.64xvs Biotechnology peers
Enterprise to Revenue
1.28xvs Biotechnology peers
Enterprise to EBITDA
9.42xvs Biotechnology peers
Gross Margin
70.56%vs Biotechnology peers
Profit Margin
7.88%vs Biotechnology peers
Operating Margin
-27.21%vs Biotechnology peers
Return on Assets (TTM)
8.54%vs Biotechnology peers
Return on Equity (TTM)
13.77%vs Biotechnology peers
Revenue (TTM)
389.42MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.63USDUpdated Jul 19, 2026Quarterly Revenue Growth
-33.10%vs Biotechnology peers
Gross Profit (TTM)
315.59MUSDvs all stocks (USD)
EBITDA (TTM)
78.77MUSDvs all stocks (USD)
Net Income (TTM)
30.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-33.12%vs Biotechnology peers
Operating Cash Flow (TTM)
70.58MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
60.82MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
418.63MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
73.01MUSDFY2025 · Dec 31, 2025Gross Profit
345.62MUSDFY2025 · Dec 31, 2025Operating Income
63.89MUSDvs all stocks (USD)
Pre-tax Income
66.26MUSDFY2025 · Dec 31, 2025Income Tax Expense
17.68MUSDFY2025 · Dec 31, 2025Net Income
48.58MUSDFY2025 · Dec 31, 2025EBIT
63.89MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
78.77MUSDFY2025 · Dec 31, 2025Research & Development
15.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
266.19MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.3300USDFY2025 · Dec 31, 2025EPS (Diluted)
0.3200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
147.79MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
147.79MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
48.58MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
56.13MUSDFY2025 · Dec 31, 2025Free Cash Flow
55.10MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
166.12MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
48.58MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.88MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
8.71MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.90MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.39MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.12MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.06MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.03MUSDFY2025 · Dec 31, 2025Net Acquisitions
-3.76MUSDFY2025 · Dec 31, 2025Other Investing Activity
-2.09MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-6.89MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-3.12MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.29MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.41MUSDFY2025 · Dec 31, 2025Shares Outstanding
148.93MSharesUpdated Jul 19, 2026Float Shares
117.96MSharesUpdated Jul 19, 2026Shares Short
7.53MSharesUpdated Jul 19, 2026Short Ratio
5.46daysvs all stocks
Short % of Shares Outstanding
6.36%vs all stocks
% Held by Insiders
2.10%vs all stocks
% Held by Institutions
76.65%vs all stocks
Total Cash (MRQ)
159.77MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.07USDUpdated Jul 19, 2026Total Debt (MRQ)
17.59MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0724xvs Biotechnology peers
Current Ratio (MRQ)
5.39xvs Biotechnology peers
Book Value per Share (MRQ)
1.63USDUpdated Jul 19, 2026Total Assets
342.65MUSDvs all stocks (USD)
Total Current Assets
277.47MUSDFY2025 · Dec 31, 2025Total Liabilities
86.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
65.18MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
21.84MUSDFY2025 · Dec 31, 2025Total Current Liabilities
64.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
166.12MUSDFY2025 · Dec 31, 2025Accounts Receivable
75.71MUSDFY2025 · Dec 31, 2025Inventory
25.34MUSDFY2025 · Dec 31, 2025Accounts Payable
14.53MUSDFY2025 · Dec 31, 2025Short-term Debt
1.50MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.79MUSDFY2025 · Dec 31, 2025Long-term Debt
16.47MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
5.37MUSDFY2025 · Dec 31, 2025Common Stock (Book)
148.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-42.68MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
256.55MUSDvs all stocks (USD)
52-Week Low
3.03USDUpdated Jul 19, 202652-Week High
7.99USDUpdated Jul 19, 202652-Week Change
-35.34%vs all stocks
Beta
1.45xvs all stocks
50-Day MA
3.79USDUpdated Jul 19, 2026200-Day MA
5.20USDUpdated Jul 19, 2026Avg 10-Day Volume
1.14MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.26MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.2000USDUpdated Jul 19, 2026Other Income / Expense
-558.00KUSDFY2025 · Dec 31, 202511 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Cash Increase With FCF And Debt Decrease
Cash up four years running while long-term debt fell for three.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: 0.08
Financial Health
Altman Z-Score 6.87: safe zoneNotable
Altman Z-Score: 6.87
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $60.82M, above the global median of $16.24MNotable
Levered free cash flow (USD): 60,823,000Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ironwood Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
476830
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tactile Systems Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lanzhou Foci Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
XPEL, Inc.
9 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Harmony Biosciences Holdings, Inc.
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedMulti-Year Cash Increase With FCF And Debt DecreaseRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And MarginMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Garmin Ltd.
8 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin